Viking Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Viking Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Viking Therapeutics: 8 sponsored US clinical trials, 1 recruiting.
Viking Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Weight Loss, with 3 trials.
Upper-quartile sponsor footprint
Viking Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383
VK2735 for Weight Management Phase 3
NCT07104500
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT06828055
VK2735 for Weight Management Phase 2
NCT06068946
A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN
NCT04973657
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH
NCT04173065
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
NCT02927184
Acute Hip Fracture Study in Patients 65 Years or Greater
NCT02578095
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Viking Therapeutics pipeline
1 recruiting of 8 indexed (13% open); 6 completed (75%).
Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Weight Loss (3 trials), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Viking Therapeutics: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Viking Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this Viking Therapeutics page
8 registered trials is a research-attention snapshot, not an endorsement of Viking Therapeutics or any single study.
- 1 of Viking Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Weight Loss is the condition Viking Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Weight Loss trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Viking Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.